{"count": 7, "results": [{"_id": "35469597", "pmid": 35469597, "title": "Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.", "journal": "J Thorac Cardiovasc Surg", "authors": ["Elkin PL", "Mullin S", "Tetewsky S", "Resendez SD", "McCray W", "Barbi J", "Yendamuri S"], "date": "2022-11-01T00:00:00Z", "doi": "10.1016/j.jtcvs.2022.02.046", "meta_date_publication": "2022 Nov", "meta_volume": "164", "meta_issue": "5", "meta_pages": "1318-1326.e3", "score": 50259.723, "text_hl": "The association of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use with overall survival (OS) after diagnosis of @<m>DISEASE_Prodromal_Symptoms</m> @DISEASE_MESH:D062706 @@@stage I@@@ @DISEASE_Carcinoma_Non_Small_Cell_Lung @DISEASE_MESH:D002289 @@@NSCLC@@@ was examined. ", "citations": {"NLM": "Elkin PL, Mullin S, Tetewsky S, Resendez SD, McCray W, Barbi J, Yendamuri S. Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 Nov;164(5):1318-1326.e3. PMID: 35469597", "BibTeX": "@article{35469597, title={Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.}, author={Elkin PL and Mullin S and Tetewsky S and Resendez SD and McCray W and Barbi J and Yendamuri S}, journal={J Thorac Cardiovasc Surg}, volume={164}, number={5}, pages={1318-1326.e3}}"}}, {"_id": "36583563", "pmid": 36583563, "pmcid": "PMC9806383", "title": "Anticancer Benefit of Metformin in Patients With Early-Stage Pancreatic Cancer: A Retrospective Cohort Study", "journal": "Technol Cancer Res Treat", "authors": ["Chen Y", "Qian FJ", "Ye ZQ", "Xie WX", "He YD", "Huang JR", "Tian L", "Gu DN"], "date": "2022-01-01T00:00:00Z", "doi": "10.1177/15330338221138208", "meta_date_publication": "2022 Jan-Dec", "meta_volume": "21", "meta_issue": "", "meta_pages": "15330338221138208", "score": 50247.332, "text_hl": "In the subgroup analysis, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use had a statistically significant association with prolongation of survival in @<m>DISEASE_Prodromal_Symptoms</m> @DISEASE_MESH:D062706 @@@stage I to II@@@ @DISEASE_Pancreatic_Neoplasms @DISEASE_MESH:D010190 @@@pancreatic cancer@@@ @SPECIES_9606 @@@patients@@@ (hazard ratio = 0.47, 95% confidence interval = 0.25-0.91), but not for advanced @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumor@@@ stage (hazard ratio for IV stage = 0.62, 95% confidence interval = 0.33-1.19), after adjustment for other risk factors. ", "citations": {"NLM": "Chen Y, Qian FJ, Ye ZQ, Xie WX, He YD, Huang JR, Tian L, Gu DN. Anticancer Benefit of Metformin in Patients With Early-Stage Pancreatic Cancer: A Retrospective Cohort Study Technol Cancer Res Treat. 2022 Jan-Dec;21():15330338221138208. PMID: 36583563", "BibTeX": "@article{36583563, title={Anticancer Benefit of Metformin in Patients With Early-Stage Pancreatic Cancer: A Retrospective Cohort Study}, author={Chen Y and Qian FJ and Ye ZQ and Xie WX and He YD and Huang JR and Tian L and Gu DN}, journal={Technol Cancer Res Treat}, volume={21}, pages={15330338221138208}}"}}, {"_id": "31677983", "pmid": 31677983, "title": "Metformin is associated with increase in lactate level in elderly patients with type 2 diabetes and CKD stage 3: A case-control study.", "journal": "J Diabetes Complications", "authors": ["Gosmanova EO", "Shahzad SR", "Sumida K", "Kovesdy CP", "Gosmanov AR"], "date": "2020-01-01T00:00:00Z", "doi": "10.1016/j.jdiacomp.2019.107474", "meta_date_publication": "2020 Jan", "meta_volume": "34", "meta_issue": "1", "meta_pages": "107474", "score": 50247.258, "text_hl": "The FDA has recently endorsed @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use in @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2D@@@ and @<m>DISEASE_Prodromal_Symptoms</m> @DISEASE_MESH:D062706 @@@stage 3 CKD@@@ (CKD3). ", "citations": {"NLM": "Gosmanova EO, Shahzad SR, Sumida K, Kovesdy CP, Gosmanov AR. Metformin is associated with increase in lactate level in elderly patients with type 2 diabetes and CKD stage 3: A case-control study. J Diabetes Complications. 2020 Jan;34(1):107474. PMID: 31677983", "BibTeX": "@article{31677983, title={Metformin is associated with increase in lactate level in elderly patients with type 2 diabetes and CKD stage 3: A case-control study.}, author={Gosmanova EO and Shahzad SR and Sumida K and Kovesdy CP and Gosmanov AR}, journal={J Diabetes Complications}, volume={34}, number={1}, pages={107474}}"}}, {"_id": "26788855", "pmid": 26788855, "pmcid": "PMC4720394", "title": "Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy", "journal": "PLoS One", "authors": ["Ezewuiro O", "Grushko TA", "Kocherginsky M", "Habis M", "Hurteau JA", "Mills KA", "Hunn J", "Olopade OI", "Fleming GF", "Romero IL"], "date": "2016-01-20T00:00:00Z", "doi": "10.1371/journal.pone.0147145", "meta_date_publication": "2016", "meta_volume": "11", "meta_issue": "1", "meta_pages": "e0147145", "score": 50060.105, "text_hl": "A second study, which also primarily included @SPECIES_9606 @@@women@@@ with early-@<m>DISEASE_Prodromal_Symptoms</m> @DISEASE_MESH:D062706 @@@stage@@@ disease (70% @<m>DISEASE_Prodromal_Symptoms</m> @DISEASE_MESH:D062706 @@@stage@@@ I disease), found improved overall survival (recurrence was not assessed), but only among @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ users with non-endometrioid histology. ", "citations": {"NLM": "Ezewuiro O, Grushko TA, Kocherginsky M, Habis M, Hurteau JA, Mills KA, Hunn J, Olopade OI, Fleming GF, Romero IL. Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy PLoS One. 2016;11(1):e0147145. PMID: 26788855", "BibTeX": "@article{26788855, title={Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy}, author={Ezewuiro O and Grushko TA and Kocherginsky M and Habis M and Hurteau JA and Mills KA and Hunn J and Olopade OI and Fleming GF and Romero IL}, journal={PLoS One}, volume={11}, number={1}, pages={e0147145}}"}}, {"_id": "26434885", "pmid": 26434885, "title": "Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study.", "journal": "Asian Pac J Cancer Prev", "authors": ["Sayed R", "Saad AS", "El Wakeel L", "Elkholy E", "Badary O"], "date": "2015-01-01T00:00:00Z", "doi": "10.7314/apjcp.2015.16.15.6621", "meta_date_publication": "2015", "meta_volume": "16", "meta_issue": "15", "meta_pages": "6621-6", "score": 50058.844, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Addition to Chemotherapy in @<m>DISEASE_Prodromal_Symptoms</m> @DISEASE_MESH:D062706 @@@Stage IV@@@ @DISEASE_Carcinoma_Non_Small_Cell_Lung @DISEASE_MESH:D002289 @@@Non-Small Cell Lung Cancer@@@: an Open Label Randomized Controlled Study.", "citations": {"NLM": "Sayed R, Saad AS, El Wakeel L, Elkholy E, Badary O. Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study. Asian Pac J Cancer Prev. 2015;16(15):6621-6. PMID: 26434885", "BibTeX": "@article{26434885, title={Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study.}, author={Sayed R and Saad AS and El Wakeel L and Elkholy E and Badary O}, journal={Asian Pac J Cancer Prev}, volume={16}, number={15}, pages={6621-6}}"}}, {"_id": "27305912", "pmid": 27305912, "title": "Proteomic modulation in breast tumors after metformin exposure: results from a \"window of opportunity\" trial.", "journal": "Clin Transl Oncol", "authors": ["Kalinsky K", "Zheng T", "Hibshoosh H", "Du X", "Mundi P", "Yang J", "Refice S", "Feldman SM", "Taback B", "Connolly E", "Crew KD", "Maurer MA", "Hershman DL"], "date": "2017-02-01T00:00:00Z", "doi": "10.1007/s12094-016-1521-1", "meta_date_publication": "2017 Feb", "meta_volume": "19", "meta_issue": "2", "meta_pages": "180-188", "score": 50048.766, "text_hl": "METHODS: In an open-label trial, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ 1500-mg PO daily was administered prior to resection in 35 non-@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Prodromal_Symptoms</m> @DISEASE_MESH:D062706 @@@stage@@@ 0-III @DISEASE_Breast_Neoplasms @DISEASE_MESH:D001943 @@@BC@@@, body mass index >=25 kg/m2. ", "citations": {"NLM": "Kalinsky K, Zheng T, Hibshoosh H, Du X, Mundi P, Yang J, Refice S, Feldman SM, Taback B, Connolly E, Crew KD, Maurer MA, Hershman DL. Proteomic modulation in breast tumors after metformin exposure: results from a \"window of opportunity\" trial. Clin Transl Oncol. 2017 Feb;19(2):180-188. PMID: 27305912", "BibTeX": "@article{27305912, title={Proteomic modulation in breast tumors after metformin exposure: results from a \"window of opportunity\" trial.}, author={Kalinsky K and Zheng T and Hibshoosh H and Du X and Mundi P and Yang J and Refice S and Feldman SM and Taback B and Connolly E and Crew KD and Maurer MA and Hershman DL}, journal={Clin Transl Oncol}, volume={19}, number={2}, pages={180-188}}"}}, {"_id": "30514262", "pmid": 30514262, "pmcid": "PMC6280542", "title": "The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 x 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients", "journal": "BMC Cancer", "authors": ["Petrera M", "Paleari L", "Clavarezza M", "Puntoni M", "Caviglia S", "Briata IM", "Oppezzi M", "Mislej EM", "Stabuc B", "Gnant M", "Bachleitner-Hofmann T", "Roth W", "Scherer D", "Haefeli WE", "Ulrich CM", "DeCensi A"], "date": "2018-12-04T00:00:00Z", "doi": "10.1186/s12885-018-5126-7", "meta_date_publication": "2018 Dec 4", "meta_volume": "18", "meta_issue": "1", "meta_pages": "1210", "score": 50046.344, "text_hl": "The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 x 2 factorial biomarker study of tertiary prevention with low-dose @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@aspirin@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @<m>DISEASE_Prodromal_Symptoms</m> @DISEASE_MESH:D062706 @@@stage I@@@-@DISEASE_Rufous_oculocutaneous_albinism @DISEASE_MESH:C537189 @@@III@@@ @DISEASE_Colorectal_Neoplasms @DISEASE_MESH:D015179 @@@colorectal cancer@@@ patients", "citations": {"NLM": "Petrera M, Paleari L, Clavarezza M, Puntoni M, Caviglia S, Briata IM, Oppezzi M, Mislej EM, Stabuc B, Gnant M, Bachleitner-Hofmann T, Roth W, Scherer D, Haefeli WE, Ulrich CM, DeCensi A. The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 x 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients BMC Cancer. 2018 Dec 4;18(1):1210. PMID: 30514262", "BibTeX": "@article{30514262, title={The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 x 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients}, author={Petrera M and Paleari L and Clavarezza M and Puntoni M and Caviglia S and Briata IM and Oppezzi M and Mislej EM and Stabuc B and Gnant M and Bachleitner-Hofmann T and Roth W and Scherer D and Haefeli WE and Ulrich CM and DeCensi A}, journal={BMC Cancer}, volume={18}, number={1}, pages={1210}}"}}]}